Ryder Files Form 144 to Sell 6,500 Restricted Shares via Fidelity
Rhea-AI Filing Summary
Ryder System, Inc. (R) filed a Form 144 reporting a proposed sale of 6,500 shares of common stock to be executed through Fidelity Brokerage Services LLC on the NYSE on 08/13/2025. The filing lists an aggregate market value of 1181505.65 and notes 40,790,636 shares outstanding.
The securities were recently acquired as restricted stock vesting on 02/07/2025 (4,802 shares) and 02/11/2025 (1,698 shares) with compensation as the payment nature. The filer indicates no securities sold in the past three months and represents that they are not aware of any undisclosed material adverse information about the issuer.
Positive
- Transparent disclosure of a proposed sale of 6,500 common shares on 08/13/2025
- Securities were acquired via restricted stock vesting on 02/07/2025 and 02/11/2025, with payment recorded as compensation
- No securities sold in the past three months is explicitly reported
Negative
- The filing records a proposed insider sale of 6,500 shares with an aggregate market value of 1181505.65
Insights
TL;DR: Routine insider sale notice for recently vested restricted shares; procedural Form 144 disclosure ahead of planned sale.
This Form 144 documents a proposed sale of 6,500 shares acquired through restricted stock vesting earlier in February 2025. The filing names Fidelity as the broker and records an aggregate market value of 1181505.65. From a market-disclosure perspective, the filing is procedural and supplies required public notice of an intended sale; it does not itself provide financial performance detail.
TL;DR: Filing shows compliance with Rule 144 requirements; signer affirms no undisclosed material information.
The notice identifies the nature of acquisition as restricted stock vesting and specifies payment as compensation, which is helpful for transparency around insider equity realizations. The filing also states there were no sales in the past three months, and includes the attestation that the seller is unaware of undisclosed material adverse information—consistent with standard Form 144 representations.